-
Product Insights
Progressive Supranuclear Palsy - Drugs In Development, 2024
Empower your strategies with our Progressive Supranuclear Palsy  – Drugs In Development, 2024 report and make more profitable business decisions. Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome, is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech, and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, and behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications. The Progressive Supranuclear Palsy...
-
Product Insights
Muscle Spasticity - Drugs In Development, 2024
Empower your strategies with our Muscle Spasticity – Drugs In Development, 2024 report and make more profitable business decisions. Muscle spasticity is a condition that causes muscles to contract, stiffen, or spasm involuntarily, affecting movement, speech, and gait. It is caused by damage or disruption to the nerve pathways that control muscle movement, usually due to brain or spinal cord injury, cerebral palsy, multiple sclerosis, or other diseases. Spasticity can range from mild to severe and can cause pain, deformity, fatigue,...
-
Product Insights
Primary Progressive Multiple Sclerosis (PPMS) - Drugs In Development, 2024
Empower your strategies with our Primary Progressive Multiple Sclerosis (PPMS) – Drugs In Development, 2024 report and make more profitable business decisions. Primary progressive multiple sclerosis (PPMS) is a rare and disabling form of MS that affects the brain, spinal cord, and optic nerves. Unlike other types of MS, PPMS does not have relapses or remissions, but causes steady worsening of neurological functions from the onset. PPMS affects about 10% of people with MS, and it occurs equally in men and...
-
Product Insights
Lennox-Gastaut Syndrome - Drugs In Development, 2024
Empower your strategies with our Lennox-Gastaut Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that starts in early childhood, usually before the age of 4 years. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and abnormal brain electric activity. The seizures are frequent, occurring daily, and difficult to treat with anti-seizure medications. The most common seizure type is tonic seizure, which causes sudden stiffening...
-
Product Insights
Narcolepsy - Drugs In Development, 2024
Empower your strategies with our Narcolepsy – Drugs In Development, 2024 report and make more profitable business decisions. Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations, and sleep paralysis. Narcolepsy treatment includes lifestyle changes, medication, and counseling. The Narcolepsy drugs in development market research report provide comprehensive information on the therapeutics under development for Narcolepsy, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Batten Disease - Drugs In Development, 2024
Empower your strategies with our Batten Disease – Drugs In Development, 2024 report and make more profitable business decisions. Batten disease, a rare genetic disorder, belongs to a group of progressive degenerative neurometabolic disorders known as the neuronal ceroid lipofuscinoses. Symptoms of Batten disease usually become apparent between five and 15 years of age. Symptoms include vision loss, lack of muscle coordination, mental retardation or decreasing mental function, emotional disturbances, seizures, muscle spasms, deterioration of muscle tone, and movement problems. The...
-
Product Insights
Tremor - Drugs In Development, 2024
Empower your strategies with our Tremor – Drugs In Development, 2024 report and make more profitable business decisions. Tremor is a neurological condition characterized by involuntary shaking or trembling movements in various body parts, primarily the hands but potentially affecting the arms, legs, head, vocal cords, and trunk, as a result of uncontrollable muscle contractions. Its impact varies, causing intermittent or constant challenges in daily tasks like writing, typing, eating, and dressing. While not life-threatening, severe cases can lead to disabilities....
-
Product Insights
Epileptic Encephalopathy - Drugs In Development, 2024
Empower your strategies with our Epileptic Encephalopathy – Drugs In Development, 2024 report and make more profitable business decisions. Epileptic encephalopathies, characterized by epileptiform abnormalities and progressive cerebral dysfunction, present in eight age-related syndromes as per the International League Against Epilepsy. Neonatal syndromes include early myoclonic encephalopathy and Ohtahara syndrome, while infancy sees West syndrome and Dravet syndrome. Childhood and adolescence encompass myoclonic status, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, and epilepsy with continuous spike waves during slow wave sleep. Diagnosis entails EEG...
-
Product Insights
Partial Seizure - Drugs In Development, 2024
Empower your strategies with our Partial Seizure – Drugs In Development, 2024 report and make more profitable business decisions. Focal onset seizures, or partial seizures, are prevalent neurological disorders marked by abnormal electrical activity in specific brain regions. Manifesting in diverse forms, symptoms range from subtle sensory disruptions to noticeable motor movements and altered consciousness. Precise diagnosis relies on clinical evaluation, neuroimaging, and electroencephalography. Managing focal onset seizures involves a range of strategies, including antiepileptic medications, surgical interventions, and lifestyle adjustments....
-
Product Insights
Intracerebral Hemorrhage - Drugs In Development, 2024
Empower your strategies with our Intracerebral Hemorrhage – Drugs In Development, 2024 report and make more profitable business decisions. Intracerebral hemorrhage (ICH), a devastating stroke subtype, involves the formation of a hematoma within the brain parenchyma, with or without extension into the ventricles. Accounting for 10-15% of all strokes, non-traumatic ICH is linked to high morbidity and mortality. Risk factors encompass chronic hypertension, amyloid angiopathy, anticoagulation, and vascular malformations. The resulting brain injury is categorized as primary, signifying initial damage by...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.